ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2013

Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux

Kevin Real1, Michael Duryee 1, Patrick Opperman 1, Evan Ryan 1, Logan Duryee 1, James O'Dell 2, Ted Mikuls 2, Daniel Anderson 1 and Geoffrey Thiele 2, 1University of Nebraska Medical Center, Omaha, NE, 2VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Cardiovascular disease, Comorbidity, receptors and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis (RA) are approximately two-fold more likely to develop cardiovascular disease (CVD).  Prior reports have suggested that “dysfunctional” HDL may explain at least part of this enhanced risk profile. It has been suggested that post-translational modifications of HDL, including those characteristic of RA, may attenuate relevant protective properties of this lipoprotein.  Specifically, studies have suggested that the irreversible post-translational modification of proteins with malondialdehyde-acetaldehyde (MAA) that are prevalent in RA synovium are also present in atherosclerotic plaque. Moreover, antibodies to MAA correlate with the development and progression of both RA and CVD.  Therefore, the purpose of this study was to examine the biologic effects resulting from the exposure of MAA-modified HDL to human macrophages that have been implicated in CVD pathogenesis. 

Methods: HDL was incubated with 2mM malondialdehye and 1mM acetaldehyde for 3 days to form the MAA adduct. PMA activated human THP-1 macrophages were subjected to 0.1, 1, 10 μg/ml of native or modified HDL in viability assays for 4 hours and ligand internalization studies for 90 minutes. Internalization studies were also performed using Chinese Hamster Ovary (CHO) cells transfected with the B-I scavenger receptor (SRB-I) shown in prior studies to mediate cellular uptake of MAA-modified protein.   Measurement of modified HDL function was tested using a fluorescent labeled cholesterol efflux assay using THP-1 cells.

Results: MAA modification of HDL was evident after 72 hours by fluorescence of the dihydropyridine ring at 398nm. THP-1 cell viability remained >95% after 4 hours of exposure to HDL-MAA. HDL-MAA was internalized at increasing concentrations compared to native HDL in both CHO cells transfected with the SRB-I receptor (p< 0.01) (A) and THP-1 cells (p< 0.0001) (B).  However, cholesterol efflux (C) was not significantly different between native HDL and HDL-MAA, indicating that cholesterol binding is not MAA-dependent.

Conclusion: Post-translational modification of HDL may contribute to the development and progression of RA and CVD comorbidity.  Increased internalization of HDL-MAA in the absence of meaningful effects on cholesterol efflux suggests that MAA modification does not alter the physiological rate of reverse cholesterol transport.  However, the preferential accumulation of HDL in THP-1 cells following MAA modification suggests that this post-translational modification (demonstrated in RA to result from inflammation and increased oxidative stress) could impact the development and progression of comorbid CVD.

Figure 1. Internalization of MAA Modified HDL Proteins and Cholesterol Efflux. -A- CHO cells transfected with SRB-I internalize HDL-MAA significantly more -p<0.01- than native HDL at 1 ug. -B- THP-1 cells internalize HDL-MAA at 0.1 and 1 ug significantly more than native HDL -p<0.0001- -C- THP-1 cells demonstrated no significant change in the cholesterol efflux despite HDL particles being modified by MAA. -N=5-


Disclosure: K. Real, None; M. Duryee, None; P. Opperman, None; E. Ryan, None; L. Duryee, None; J. O'Dell, None; T. Mikuls, BMS, 2, Horizon, 2; D. Anderson, None; G. Thiele, None.

To cite this abstract in AMA style:

Real K, Duryee M, Opperman P, Ryan E, Duryee L, O'Dell J, Mikuls T, Anderson D, Thiele G. Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/increased-accumulation-of-malondialdehyde-acetaldehyde-modified-hdl-in-macrophage-without-decreased-cholesterol-efflux/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-accumulation-of-malondialdehyde-acetaldehyde-modified-hdl-in-macrophage-without-decreased-cholesterol-efflux/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology